A5071074041- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Diet and metabolism studies
- Regulation of Appetite and Obesity
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Bariatric Surgery and Outcomes
- Adipose Tissue and Metabolism
- Diabetes and associated disorders
- Biochemical Analysis and Sensing Techniques
- Neuropeptides and Animal Physiology
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Neuroendocrine Tumor Research Advances
- Diet, Metabolism, and Disease
- Pharmacology and Obesity Treatment
- Pancreatitis Pathology and Treatment
- Adipokines, Inflammation, and Metabolic Diseases
- Receptor Mechanisms and Signaling
- Nutritional Studies and Diet
- Stress Responses and Cortisol
- Muscle metabolism and nutrition
- Hormonal Regulation and Hypertension
- Pancreatic and Hepatic Oncology Research
- Obesity and Health Practices
- Diabetes, Cardiovascular Risks, and Lipoproteins
Duke University
2016-2025
Duke Medical Center
2016-2025
Duke University Hospital
2015-2024
Eli Lilly (United States)
2023
University of Cincinnati Medical Center
2008-2021
University of Chicago
2021
Cincinnati VA Medical Center
2010-2018
University of Cincinnati
2009-2018
Area Cooperative Education Services
2018
Winston-Salem State University
2018
The American Diabetes Association and the European for Study of convened a panel to update prior position statements, published in 2012 2015, on management type 2 diabetes adults. A systematic evaluation literature since 2014 informed new recommendations. These include additional focus lifestyle self-management education support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, surgical interventions, are recommended. With regards medication management,...
The American Diabetes Association and the European for Study of have briefly updated their 2018 recommendations on management hyperglycemia, based important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor reduce major adverse events (MACE), hospitalization heart failure (hHF), death,...
Untested alternative weight loss diets, such as very low carbohydrate have unsubstantiated efficacy and the potential to adversely affect cardiovascular risk factors. Therefore, we designed a randomized, controlled trial determine effects of diet on body composition Subjects were randomized 6 months either an ad libitum or calorie-restricted with 30% calories fat. Anthropometric metabolic measures assessed at baseline, 3 months, months. Fifty-three healthy, obese female volunteers (mean mass...
A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of adds established clinical benefits selective agonists in type 2 diabetes mellitus (T2DM).LY3298176 is a fatty acid modified peptide with agonist activity designed for once-weekly subcutaneous administration. LY3298176 characterised vitro, using signaling functional assays cell lines expressing recombinant or endogenous incretin receptors, vivo body weight, food intake, insulin...
Hyperglycemia during critical illness is common and associated with increased mortality. Intensive insulin therapy has improved outcomes in some, but not all, intervention trials. It unclear whether the benefits of treatment differ among specific patient populations. The purpose study was to determine association between hyperglycemia risk- adjusted mortality critically ill patients separate groups stratified by admission diagnosis. A secondary risk from varies intensive care unit type,...
Islet amyloid polypeptide (IAPP) has been identified as the major constituent of pancreatic non-insulin-dependent diabetes mellitus (NIDDM) and is also present in normal beta-cell secretory granules. To determine whether IAPP a product, we measured quantity IAPP-like immunoreactivity (IAPP-LI), insulin, glucagon released into 5 ml incubation medium during 2-h monolayer cultures (n = 5) neonatal (3- to 5-day-old) Sprague-Dawley rat pancreases under three conditions: 1.67 mM glucose, 16.7...
Glucose control and weight loss are cornerstones of type 2 diabetes treatment. Currently, only glucagon-like peptide-1 (GLP1) analogs able to achieve both glucose tolerance. Both body regulated by the brain, which contains GLP1 receptors (GLP1R). Even though brain is poised mediate effects analogs, it remains unclear whether glucose- weight-lowering long-acting GLP1R agonists via direct action on CNS or result downstream activation afferent neuronal GLP1R. We generated mice with either...
OBJECTIVE Gastric bypass (GB) surgery is associated with postprandial hyperinsulinemia, and this effect accentuated in postsurgical patients who develop recurrent hypoglycemia. Plasma levels of the incretin glucagon-like peptide 1 (GLP-1) are dramatically increased after GB, suggesting that its action contributes to alteration glucose regulation. The aim study was establish role GLP-1 on insulin secretion GB. RESEARCH DESIGN AND METHODS Twelve asymptomatic individuals previous GB (Asym-GB),...
OBJECTIVE The orexigenic gut hormone ghrelin and its receptor are present in pancreatic islets. Although reduces insulin secretion rodents, effect on humans has not been established. goal of this study was to test the hypothesis that circulating suppresses glucose-stimulated healthy subjects. RESEARCH DESIGN AND METHODS Ghrelin (0.3, 0.9 1.5 nmol/kg/h) or saline infused for more than 65 min 12 patients (8 male/4 female) 4 separate occasions a counterbalanced fashion. An intravenous glucose...
Glucagon-like peptide-1 (GLP-1) promotes glucose homeostasis through regulation of islet hormone secretion, as well hepatic and gastric function. Because GLP-1 is also synthesized in the brain, where it regulates food intake, we hypothesized that central system tolerance well.We used tests hyperinsulinemic-euglycemic clamps to assess role on tolerance, insulin peripheral sensitivity. Finally, situ hybridization was examine colocalization receptors with neuropeptide tyrosine...
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that secreted during meal absorption and essential for normal glucose homeostasis. However, the relatively low plasma levels rapid metabolism of GLP-1 raise questions as to whether direct endocrine action on target organs, such islet cells, account all its effects tolerance. Recently, alternative neural pathway initiated by sensors in hepatic portal region has been proposed mediate activity. We hypothesized visceral afferent neurons...
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, nonalcoholic steatohepatitis. Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by selective agonist. Therefore, we hypothesized integrated potency signaling properties provide unique pharmacological profile tailored improving broad metabolic control. Here, establish methodology calculating...
Glucagon, an essential regulator of glucose homeostasis, also modulates lipid metabolism and promotes weight loss, as reflected by the wasting observed in glucagonoma patients. Recently, coagonist peptides that include glucagon agonism have emerged promising therapeutic candidates for treatment obesity diabetes. We developed a novel stable soluble receptor (GcgR) agonist, which allowed vivo dissection action. As expected, chronic GcgR mice resulted hyperglycemia lower body fat plasma...